European Union - English - EMA (European Medicines Agency)

merck sharp dohme limited - vorapaxar sulfate - myocardial infarction - antithrombotic agents - zontivityis indicated for the reduction of atherothrombotic events in adult patients with- a history of myocardial infarction (mi)co-administered with acetylsalicylic acid (asa) and, where appropriate, clopidogrel; or- symptomatic peripheral arterial disease(pad), co-administered with acetylsalicylic acid (asa) or, where appropriate, clopidogrel.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atorvastatin calcium trihydrate 10.844mg equivalent to atorvastatin 10 mg;   - film coated tablet - 10 mg - active: atorvastatin calcium trihydrate 10.844mg equivalent to atorvastatin 10 mg   excipient: arginine colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry white 85f18378 opadry white oy-b-28920 amb sodium carbonate - lorstat is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. lorstat is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atorvastatin calcium trihydrate 21.688mg equivalent to atorvastatin 20 mg;   - film coated tablet - 20 mg - active: atorvastatin calcium trihydrate 21.688mg equivalent to atorvastatin 20 mg   excipient: arginine colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry white 85f18378 opadry white oy-b-28920 amb sodium carbonate - lorstat is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. lorstat is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atorvastatin calcium trihydrate 43.376mg equivalent to atorvastatin 40 mg;   - film coated tablet - 40 mg - active: atorvastatin calcium trihydrate 43.376mg equivalent to atorvastatin 40 mg   excipient: arginine colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry white 85f18378 opadry white oy-b-28920 amb sodium carbonate - lorstat is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. lorstat is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - atorvastatin calcium trihydrate 86.751mg equivalent to atorvastatin 80 mg;   - film coated tablet - 80 mg - active: atorvastatin calcium trihydrate 86.751mg equivalent to atorvastatin 80 mg   excipient: arginine colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry white 85f18378 opadry white oy-b-28920 amb sodium carbonate - lorstat is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. lorstat is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ciprofloxacin hydrochloride 3.5 mg/ml equivalent to ciprofloxacin 3.0 mg/ml;   - eye drops, solution - 3 mg/ml - active: ciprofloxacin hydrochloride 3.5 mg/ml equivalent to ciprofloxacin 3.0 mg/ml   excipient: benzalkonium chloride disodium edetate glacial acetic acid hydrochloric acid mannitol sodium acetate sodium hydroxide water for injection - treatment of corneal ulcers, conjunctivitis and blepharitis caused by susceptible strains of bacteria in adults and children 12 months of age and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

air flow products limited - escitalopram oxalate 12.776mg equivalent to escitalopram 10 mg - film coated tablet - 10 mg - active: escitalopram oxalate 12.776mg equivalent to escitalopram 10 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose e-15 hypromellose e-5 macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

air flow products limited - escitalopram oxalate 25.552mg equivalent to escitalopram 20 mg - film coated tablet - 20 mg - active: escitalopram oxalate 25.552mg equivalent to escitalopram 20 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose e-15 hypromellose e-5 macrogol 400 magnesium stearate microcrystalline cellulose purified talc titanium dioxide - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.